1.Polycystic liver disease: an overview of clinical manifestations, diagnosis, and treatment
Kosin Medical Journal 2023;38(2):75-86
Polycystic liver disease (PLD) is a hereditary disease characterized by the presence of 20 or more liver cysts. It is classified into three types: isolated autosomal dominant PLD, PLD with autosomal dominant polycystic kidney disease, and PLD with autosomal recessive polycystic kidney disease. Genetic alterations, ciliary dysfunction of the biliary epithelial cells, and aberrant cell signaling pathways are the main factors contributing to the pathophysiology of PLD; however, other complicated mechanisms are also involved. The Gigot and Schnelldorfer classifications are widely used in clinical practice. Most patients with PLD are asymptomatic; however, a few patients with advanced-stage disease may develop symptoms and complications that impair their quality of life and require treatment. The known treatment options for PLD are somatostatin analogues, aspiration with sclerotherapy, fenestration, hepatic resection, and liver transplantation. Although liver transplantation remains the only curative treatment for PLD, medical therapies are gradually being developed with the increasing knowledge of the disease’s pathophysiology. This review focuses on the clinical manifestations and diagnosis of PLD, as well as treatment strategies, to support clinicians regarding the clinical management of the disease.
2.Spinal anesthesia for urgent Cesarean section in a patient with uncontrolled hyperthyroidism due to Graves’ disease - A case report -
Sangyoong PARK ; Soron CHOI ; Joonho JEONG ; Jeongho KIM
Anesthesia and Pain Medicine 2020;15(3):319-324
Background:
Effective treatment of Graves’ disease during pregnancy is important because uncontrolled hyperthyroidism is associated with increased fetal and maternal morbidity and mortality. While there have been case reports of patients with Graves’ disease who failed to achieve euthyroid state during pregnancy, anesthesiologists rarely encounter patients with uncontrolled hyperthyroidism undergoing urgent Cesarean section.Case: A 31-year-old pregnant patient had uncontrolled hyperthyroidism due to Graves’ disease despite medical treatment. Her signs and symptoms suggested fetal distress and aggravation of the disease, leading to hospitalization. After a failed induction for vaginal delivery, an urgent Cesarean section was performed under spinal anesthesia via an interlaminar approach using 9 mg of 0.5% heavy bupivacaine and 20 μg of fentanyl. It resulted in successful delivery, with no perioperative complications for the mother and neonate.
Conclusions
This case demonstrates that spinal anesthesia may provide clinical stability to patients with uncontrolled hyperthyroidism undergoing urgent Cesarean section.
3.Post-Traumatic Growth: The Conception and Neurobiology.
Sang Won JEON ; Changsu HAN ; Joonho CHOI ; Jong Woo PAIK ; Chi Un PAE ; Jeong Ho CHAE
Korean Journal of Psychopharmacology 2015;26(1):1-9
Stress and trauma research has traditionally focused on negative sequelae of adversity. Recently, research has begun to focus on positive outcomes, specifically post-traumatic growth (PTG) - "positive change experienced as a result of the struggle with trauma" - which emphasizes the transformative potential of one's experiences with highly stressful events and circumstances. This article describes the concept of PTG at three different perspectives. In addition we reviewed the neurobiological factors and mechanism of PTG. It has shown that PTG is mediated by adaptive changes in several neural circuits involving numerous neurotransmitter and molecular pathways. Much more study is required to achieve a deeper understanding the biological and psychological underpinnings of PTG, as well as the interactions between these factors. After all, the clinical phenomenology of PTG is very important for mental growth after trauma. The findings of this article provide further directions for research and clinical implication of PTG.
Fertilization*
;
Life Change Events
;
Neurobiology*
;
Neurotransmitter Agents
4.A Rare Case of Metastatic Brain Tumor From Classic Biphasic Pulmonary Blastoma Presented as Intracerebral Hemorrhage
Sanghyeok PARK ; Joonho BYUN ; Sang Woo SONG ; Young-Hoon KIM ; Chang-Ki HONG ; Jeong Hoon KIM
Brain Tumor Research and Treatment 2021;9(2):81-86
Pulmonary blastoma is a rare type of primary lung cancer that accounts for only 0.25%-0.5% of all lung malignancies. Pulmonary blastoma consists of three subgroups: classic biphasic pulmonary blastoma (CBPB), pleuropulmonary blastoma, and well-differentiated fetal adenocarcinoma. Due to the rarity of the tumor, metastatic brain tumor from CBPB is extremely rare, and only 13 cases, including our case, have been reported. A 60-year-old woman who underwent left upper lobectomy of the lung because of pathologically diagnosed as CBPB 5 months ago, suddenly lost consciousness and presented with stupor mental status. The emergent CT scan showed a large, 51 mL, intracerebral hemorrhage on left parieto-occipital lobe with midline shifting. The patient underwent emergent craniotomy, and a hypervascular tumor was identified during the operation. Histopathologic examination reported metastatic pulmonary blastoma, CBPB. The patient has been in a vegetative state, but there has been no evidence of recurrence over a 6-month follow-up period. We report a rare case of brain metastasis from CBPB presenting with altered mentality due to massive tumor bleeding. This is the only reported case of brain metastasis from CBPB presenting with acute intracerebral hemorrhage.
5.Extraventricular Neurocytoma: Clinical Investigation of Heterogenous Prognosis
Joonho BYUN ; Moinay KIM ; Sang Woo SONG ; Young-Hoon KIM ; Chang Ki HONG ; Jeong Hoon KIM
Brain Tumor Research and Treatment 2022;10(1):22-28
Background:
Extraventricular neurocytoma (EVN) is an extremely rare neuronal neoplasm that arises outside the ventricle. The clinical implication of the heterogenous prognosis of this rare tumor has not yet been clarified. Herein, we analyzed our institutional series of EVN.
Methods:
A total of eight consecutive cases were enrolled and investigated. The prognosis of EVN was analyzed and compared to that of central neurocytoma (CN).
Results:
There were two male and six female patients, and the median age was 36.5 years. The median tumor size was 38 mm, and the most common location of the tumor was the frontal lobe (3, 37.5%), followed by the parietal and temporal lobes. In brain imaging, four (50%) tumors showed peritumoral edema and three (37.5%) tumors showed calcification. All patients underwent gross total resection, and two (25%) underwent adjuvant radiotherapy. The 5-year overall survival (OS) was 55.6%, and the 2-year progression-free survival (PFS) was 42.9%. The OS and PFS of EVN were poor compared to those of CN. Although EVN is a single disease entity, individual patients showed varying prognosis. One patient showed no recurrence during the 7-year follow-up period; however, another patient had a recurrence 4 months after surgery and died 2 years later.
Conclusion
EVN may be a heterogenous disease entity. Additional cases with long-term followup are needed to develop optimal management protocols.
6.Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis
Joonho JEONG ; Jung Woo SHIN ; Seok Won JUNG ; Eun Ji PARK ; Neung Hwa PARK
Clinical and Molecular Hepatology 2022;28(2):254-264
Background/Aims:
Tenofovir alafenamide (TAF) has shown less favorable effect on lipids compared to tenofovir disoproxil fumarate (TDF) in clinical trials. However, data regarding these outcomes in patients with chronic hepatitis B (CHB) are scarce. Therefore, this study aimed to evaluate the effect of TAF on the lipid in patients with CHB.
Methods:
A total of 237 TAF-treated CHB patients compared with TDF, inactive CHB, and non-hepatitis B virus (HBV)-infected control groups using propensity score matching (PSM).
Results:
Following PSM, each analysis was conducted on cohorts via the matching of 70:140 (TAF:TDF), 89:89 (TAF:inactive CHB), 140:560 (TAF:non-HBV infected control), and 368:1,472 (TDF:non-HBV-infected control). A significant decrease in the total cholesterol (TC) level was noted at 48 weeks in the TDF group compared to the TAF group (176.3±32.9 vs. 156.7±27.7, P<0.001) and the non-HBV-infected control group (175.0±29.5 vs. 156.2±28.3, P<0.001). However, no significant change in TC was observed in the TAF group and inactive CHB or non-HBV-infected control groups at 48 weeks. For the subgroup analyses of TAF vs. non-HBV-infected control subjects and inactive CHB patients whose detailed lipid profile information were available, no between-group differences in TC, low-density lipoprotein (LDL)-cholesterol, highdensity lipoprotein (HDL)-cholesterol, TC/HDL ratio, and LDL/HDL ratio were observed at 48 weeks.
Conclusions
TDF seems to have a lipid-lowering effect compared to the non-HBV-infected control and TAF-treated groups. However, in real practice, TAF might not worsen the lipid profiles of subjects compared to non-HBV-infected controls and patients with inactive CHB.
7.Correction: Mixed Neuroendocrine-non-neuroendocrine Neoplasm of the Stomach that is Distributed in Depth on the Same Tumor: Inconsistent with the Definition of Mixed Adenoneuroendocrine Carcinoma in the 2010 World Health Organization Classification of Tumors of the Digestive System
Joonho JEONG ; Kyoungwon JUNG ; Jae Hyun KIM ; Sung Eun KIM ; Won MOON ; Moo In PARK ; Seun Ja PARK
The Korean Journal of Gastroenterology 2020;75(1):63-63
This correction is being published to correct the 1st author's English name in above article.
8.Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir
Seung Bum LEE ; Joonho JEONG ; Jae Ho PARK ; Seok Won JUNG ; In Du JEONG ; Sung-Jo BANG ; Jung Woo SHIN ; Bo Ryung PARK ; Eun Ji PARK ; Neung Hwa PARK
Clinical and Molecular Hepatology 2020;26(3):364-375
Background/Aims:
Low-level viremia (LLV) after nucleos(t)ide analog treatment was presented as a possible cause of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). However, detailed information on patients’ adherence in the real world was lacking. This study aimed to evaluate the effects of LLV on HCC development, mortality, and cirrhotic complications among patients according to their adherence to entecavir (ETV) treatment.
Methods:
We performed a retrospective observational analysis of data from 894 consecutive adult patients with treatment-naïve CHB undergoing ETV treatment. LLV was defined according to either persistent or intermittent episodes of <2,000 IU/mL detectable hepatitis B virus DNA during the follow-up period. Good adherence to medication was defined as a cumulative adherence ≥90% per study period.
Results:
Without considering adherence in the entire cohort (n=894), multivariate analysis of the HCC incidence showed that LLV was an independent prognostic factor in addition to other traditional risk factors in the entire cohort (P=0.031). Good adherence group comprised 617 patients (69.0%). No significant difference was found between maintained virologic response and LLV groups in terms of the incidence of liver-related death or transplantation, HCC, and hepatic decompensation in good adherence group, according to multivariate analyses.
Conclusions
In patients with treatment-naïve CHB and good adherence to ETV treatment in the real world, LLV during treatment is not a predictive factor for HCC and cirrhotic complications. It may be unnecessary to adjust their antiviral agent for patients with good adherence who experience LLV during ETV treatment.
9.The Effect of Anti-reflux Therapy on Patients Diagnosed with Minor Disorders of Peristalsis in High-resolution Manometry.
Joonho JEONG ; Sung Eun KIM ; Moo In PARK ; Seun Ja PARK ; Won MOON ; Jae Hyun KIM ; Kyoungwon JUNG ; Youn Jung CHOI ; Jun Yeob LEE ; Young Dal LEE
The Korean Journal of Gastroenterology 2017;69(4):212-219
BACKGROUND/AIMS: Minor disorders of peristalsis are esophageal motility disorders categorized by the Chicago Classification (CC), version 3.0, which was announced in 2014. This study evaluated the efficacy of anti-reflux therapy in patients with minor peristaltic disorders. METHODS: Patients with minor peristaltic disorders in accordance with CC v3.0 were included. We reviewed the medical records of patients with esophageal high-resolution manometry findings, and investigated the demographic and clinical information as well as the medical therapy. Thereafter, the response to treatment was assessed after at least 4 weeks of treatment. RESULTS: A total of 24 patients were identified as having minor disorders of peristalsis from January 2010 to December 2015. The mean follow-up period was 497 days, and there were 17 patients (70.8%) patients with ineffective esophageal motility. In terms of anti-reflux therapy, proton pump inhibitors (PPIs) with prokinetic agents and PPIs alone were prescribed in 19 patients (79.2%) and 5 patients (20.8%), respectively. When the rate of response to the treatment was assessed, the responders rate (complete+satisfactory [≥50%] responses) was 54.2% and the non-responders rate (partial [<50%]+refractory responses) was 45.8%. Patients in the responder group were younger than those in the non-responder group (p=0.020). Among them, 13 patients underwent 24-hour multichannel intraluminal impedance-pH, and 10 patients (76.9%) were pathologic gastroesophageal reflux. CONCLUSIONS: The majority of esophageal minor peristaltic disorders were accompanied by gastroesophageal reflux, and therefore, they might respond to acid inhibitor. Further well-designed, prospective studies are necessary to confirm the effect of anti-reflux therapy in these patients.
Classification
;
Esophageal Motility Disorders
;
Follow-Up Studies
;
Gastroesophageal Reflux
;
Humans
;
Manometry*
;
Medical Records
;
Peristalsis*
;
Prospective Studies
;
Proton Pump Inhibitors
;
Proton Therapy
;
Treatment Outcome
10.Posttraumatic Growth and Resilience: Assessment and Clinical Implications.
Sang Won JEON ; Changsu HAN ; Joonho CHOI ; Chi Un PAE ; Jeong Ho CHAE ; Young Hoon KO ; Ho Kyoung YOON ; Changwoo HAN
Journal of Korean Neuropsychiatric Association 2015;54(1):32-39
Stress and trauma research has traditionally focused on the negative sequela of adversity. Recently, research has begun to focus on positive outcomes, specifically posttraumatic growth (PTG)-"positive change experienced as a result of the struggle with trauma"-which emphasizes the transformative potential of one's experiences with highly stressful events and circumstances. For evaluation of PTG, resilience is very important. Resilience refers to a person's ability to successfully adapt to acute stress, trauma or more chronic forms of adversity, maintaining psychological well-being. This article introduces several measurement scales for assessment of PTG and resilience. In addition, we suggest psychological techniques for facilitating PTG focusing on the relationship with adaptation after trauma. Finally, we discuss the applicability of a therapeutic approach for PTG in clinical practice. The systemic review of this article will provide further directions for PTG and resilience.
Life Change Events
;
Psychological Techniques
;
Psychology
;
Weights and Measures